Treating dyspareunia caused by vaginal atrophy: A review of treatment options using vaginal estrogen therapy

International Journal of Women's Health

Volumn 1, Issue 1, 2009, Pages 105-111

  Kingsberg, Sheryl A ^a   Kellogg, S ^b   Krychman, M ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Southern California Center for Sexual Health and Survivorship Medicine   (United States)

Author keywords

Dyspareunia; Postmenopausal vulvovaginal atrophy; Vaginal estrogen therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN;

CLINICAL ASSESSMENT; CLINICAL FEATURE; DRUG SAFETY; DYSPAREUNIA; ESTROGEN THERAPY; FEMALE; HEALTH EDUCATION; HUMAN; HYGIENE; LIFESTYLE MODIFICATION; LUBRICATION; MASTALGIA; PATIENT SATISFACTION; PHYSICAL EXAMINATION; POSTMENOPAUSE; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL FUNCTION; TREATMENT PLANNING; VAGINA ATROPHY; VAGINA BLEEDING; VAGINAL DRYNESS;

EID: 77953445747     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s4872     Document Type: Review

References (34)

1. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3):357-336.
2. Kingsberg SA. Maintaining and evaluating quality of life after menopause. The Female Patient. 1996; May Suppl.
3. Utian WH, Janata JW, Kingsberg SA and Patrick LD. Determinants and Quantification of Quality of Life after Menopause: The Utian Menopause Quality of Life Score. In Aso T, Yamahara T, Fujimoto S, editors. Menopause at the Millenium. Parthenon Publishing, New York; 2000. p. 00-00.
4. World Health Organization. Education and treatment in human sexuality: the training of health professionals. Report of a WHO meeting. Q Corporation, 49 Sheridan Avenue, Albany, NY 12210, 2000.
5. Nyirjesy P. Postmenopausal vaginitis. Curr Infect Dis Rep 2007;9:480-484.
6. Bachmann G, Eberg GA Burd ID. Vulvovaginal complaints. In: Lobo RA, editor. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Philadelphia PA: Lippincott Williams & Wilkins; 1999. p. 195-201.
7. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet 2005;88(2):222-228.
8. Katz A. When sex hurts: menopause-related dyspareunia. Vaginal dryness and atrophy can be treated. Am J Nurs. 2007;107(7):34-6, 39.
9. Freedman M. Vaginal pH, estrogen and genital atrophy. Menopause Management. 2008;17(4):9-13.
10. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47.
11. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15(4 Pt 1): 661-666.
12. Kelley C. Estrogen and its effect on vaginal atrophy in post-menopausal women. Urol Nurs. 2007;27(1):40-45.
13. Carcio H. Urogenital atrophy. A new approach to vaginitis diagnosis. Adv Nurse Pract 2002;10(10):40-8, 51.
14. Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol 2008;51(3):549-555.
15. Bachman GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090-3096.
16. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003/ 2005;(4):CD001500.
17. Woodcock J. Bridging what is known and what is not known: FDA perspective and response. US FDA CDER [serial online] 2002; http:// www.fda.gov.drugs. Accessed January 25, 2009.
18. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118(suppl 12B):163-165.
19. American College of Obstetricians and Gynecologists Task Force on Hormone Therapy. Genitourinary tract changes. Obstet Gynecol 2004;104(4 Suppl):56S-61S.
20. Coulton CJ. Decision making in support: patient perceptions and preferences. J Clin Epidemiol 1990:43(Suppl):51S-54S.
21. Pace DT. Menopause: studying the research. Nurse Pract 2006;31(8):17-23.
22. Smith PE. Menopause assessment, treatment, and patient education. Nurse Pract 2005;30(2):32-43.
23. Theroux R, Taylor K. Women's decision making about the use of hormonal and nonhormonal remedies for the menopausal transition. J Obstet Gynecol Neonatal Nurs. 2003;32(6):712-723.
24. Aber CS, Arathuzik D, Righter AR. Women's perceptions and concerns about menopause. Clin Excell Nurse Pract 1998;2(4):232-238.
25. Hutcherson HY, Kingsberg SA, Krychman ML, et al. A positive approach to female sexual health: A summary report. Female Patient. 2009;(Suppl April):1-6.
26. Estrogen and estrogen with progestin therapies for postmenopausal women. US FDA CDER [serial online] 2008; http://www.fda.gov.drugs. Accessed January 25, 2009.
27. Robb-Nicholson C. By the way, doctor. My doctor prescribed a low-dose vaginal estrogen cream, applied twice a week, for atrophic vaginitis. I've heard this dose is so low that it carries no health risk. Do you agree? Harv Womens Health Watch. 2007;15(3):7.
28. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008;93(12):4567-4575.
29. Bachman G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause. 2009; In Press.
30. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8(1):83-92.
31. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112(5):1053-1060.
32. Basson R. Taking the sexual history, part 1: Eliciting the sexual concerns of your patient in primary care. Med Aspects Hum Sex. 2000;1(1):13-18.
33. Plaut SM, Graziottin A, Heaton JPW. FastFacts: Sexual Dysfunction. Health Press, 2004.
34. Kingsberg SA, Janata JW. Female sexual disorders: Assessment, diagnosis and treatment. Urol Clin N Am. 2007;34(4):497-506.